With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

ImmunityBio, Inc. , a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

But there’s a new emerging treatment of “neural grafts” that offers a more direct approach by aiming to replace the damaged brain cells themselves. In fact, significant clinical trials are ...